Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
Author:
Affiliation:
1. Hull York Medical School Whitby Group Practice Spring Vale Medical Centre Whitby UK
2. Amgen (Europe) GmbH Zug Switzerland
3. Ashgate Medical Practice Chesterfield UK
Funder
Amgen (Europe) GmbH
Publisher
Hindawi Limited
Subject
General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.12881
Reference77 articles.
1. NicholsM TownsendN Luengo‐FernandezR et al.European Cardiovascular Disease Statistics 2012. European Heart Network Brussels European Society of Cardiology Sophia Antipolis 2012.http://www.ehnheart.org/cvd-statistics.html. Accessed January 8 2016.
2. 2016 European Guidelines on cardiovascular disease prevention in clinical practice
3. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
4. NICE clinical guideline on lipid modification 2014.https://www.nice.org.uk/guidance/cg181. Accessed May 20 2016.
5. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Low LDL-C: Is It all Good News?;Current Atherosclerosis Reports;2024-09-10
2. Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers;Lipids in Health and Disease;2024-05-25
3. Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy;Journal of Clinical Medicine;2024-03-25
4. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management;Journal of Clinical Medicine;2024-02-22
5. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy;Cellular and Molecular Biology;2023-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3